top of page


12 months


University of California San Francisco


EGCG was discovered as an antifibrotic in pre-clinical in vivo studies with a mechanism of action blocking collagen accumulation that was published in 2017. A pilot study was conducted in 2019 in which EGCG given daily for two weeks to UCSF ILD patients scheduled for diagnostic lung biopsy. 

Biopsies were analyzed for pro-fibrotic markers in tissues from 10 patients given EGCG and 10 controls. EGCG markedly attenuated pro-fibrotic signaling and new collagen accumulation in IPF patient tissues. Data from this study suggest that patients with IPF would benefit from EGCG treatment by reducing fibrogenesis, warranting a longer clinical trial in patients with this condition. 

The investigation was supported by a grant from Three Lakes Foundation and was led by Harold A. Chapman, MD, a Professor in the School of Medicine at the University of California, San Francisco. "Reversal of TGFβ1-Driven Profibrotic State in Patients with Pulmonary Fibrosis" was published in the New England Journal of Medicine. To read the article, a PDF can be found in the Publications section of this website or by clicking here.

Enlil Therapeutics

Three Lakes Foundation has provided funding to support Enlil Therapeutics in its quest to identify compounds that activate telomerase.

B4PF: Understanding Early Disease

To develop therapies that prevent the development of PF, it is essential to study the earliest aspects of disease pathogenesis.

A Global Collaboration for PF

Centre of Research Excellence in Pulmonary Fibrosis (CRE-PF) is a clinically focused research program funded by the Australian National Health and Medical Research Council.

Additional Programs

bottom of page